Fintel reports that on January 20, 2026, BTIG initiated coverage of Opus Genetics (NasdaqCM:IRD) with a Buy recommendation.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes.

Tempus AI's diagnostics segment shows strong pricing power, with Oncology ASP rising from $1,630 to over $2,200. Read why TEM ...

Turkey became a global hotspot for hair restoration for a reason: experienced teams, modern clinics, and a well-built medical ...

Pharma companies are planning to increase the price of more than 350 medications, including COVID vaccines and cancer ...

Mendel’s monastery garden experiments went largely unnoticed during his life, but their implications would ripple through ...

Non-protein-coding genes have been linked to a hereditary condition, retinitis pigmentosa, that causes progressive blindness.

A team of researchers has conducted the largest and most comprehensive genome-wide association study (GWAS) to date of ...

Health Secretary RFK Jr. removed four members of the Advisory Commission on Childhood Vaccines, which advises on Vaccine ...

Rolling coverage of the latest economic and financial news ...

Ludovic Orlando's Horses is an enthralling account by one of the main players, detailing how genetics has rewritten what we ...

Researchers from CSIRO, Australia's national science agency, have unlocked the most detailed genetic blueprint yet of a major ...